Literature DB >> 8912370

Radionuclides and carrier molecules for therapy.

J Zweit1.   

Abstract

Although radionuclide therapy has been around for a long time, this modality of cancer treatment has been limited mainly to the use of [32P]-phosphate and [131I]-sodium iodide. The last few years, however, have seen an increased interest in this area due to new developments of radionuclides and carrier molecules that may provide selective targeting of tumour sites. The potential of this technique can be further realized if the radionuclide is carefully selected to match both the localization of the carrier molecule and tumour morphology. This paper briefly reviews radionuclides in current use and potential candidates for targeted therapy. Decay characteristics, production methods and relevant chemical properties are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912370     DOI: 10.1088/0031-9155/41/10/004

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  16 in total

1.  Chemoradionuclide therapy with 186re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response.

Authors:  Anuradha Soundararajan; Ande Bao; William T Phillips; Linda M McManus; Beth A Goins
Journal:  Cancer Biother Radiopharm       Date:  2011-08-11       Impact factor: 3.099

2.  Post-lumpectomy intracavitary retention and lymph node targeting of (⁹⁹m)Tc-encapsulated liposomes in nude rats with breast cancer xenograft.

Authors:  Shihong Li; Beth Goins; William T Phillips; Marcela Saenz; Pamela M Otto; Ande Bao
Journal:  Breast Cancer Res Treat       Date:  2010-12-23       Impact factor: 4.872

3.  Interventional therapy of head and neck cancer with lipid nanoparticle-carried rhenium 186 radionuclide.

Authors:  J Tyler French; Beth Goins; Marcela Saenz; Shihong Li; Xavier Garcia-Rojas; William T Phillips; Randal A Otto; Ande Bao
Journal:  J Vasc Interv Radiol       Date:  2010-05-15       Impact factor: 3.464

4.  Hyperpolarized (89)Y offers the potential of direct imaging of metal ions in biological systems by magnetic resonance.

Authors:  Matthew E Merritt; Crystal Harrison; Zoltan Kovacs; Preeti Kshirsagar; Craig R Malloy; A Dean Sherry
Journal:  J Am Chem Soc       Date:  2007-10-10       Impact factor: 15.419

5.  A comparison of PET imaging characteristics of various copper radioisotopes.

Authors:  Heather Ann Williams; Simon Robinson; Peter Julyan; Jamal Zweit; David Hastings
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-29       Impact factor: 9.236

Review 6.  Therapeutic radionuclides in nuclear medicine: current and future prospects.

Authors:  Chai-Hong Yeong; Mu-hua Cheng; Kwan-Hoong Ng
Journal:  J Zhejiang Univ Sci B       Date:  2014-10       Impact factor: 3.066

7.  Chemoradionuclide therapy with 186Re-labeled liposomal doxorubicin in combination with radiofrequency ablation for effective treatment of head and neck cancer in a nude rat tumor xenograft model.

Authors:  Anuradha Soundararajan; Gerald D Dodd; Ande Bao; William T Phillips; Linda M McManus; Thomas J Prihoda; Beth A Goins
Journal:  Radiology       Date:  2011-10-24       Impact factor: 11.105

8.  Brachytherapy using injectable seeds that are self-assembled from genetically encoded polypeptides in situ.

Authors:  Wenge Liu; Jonathan McDaniel; Xinghai Li; Daisuke Asai; Felipe Garcia Quiroz; Jeffery Schaal; Ji Sun Park; Michael Zalutsky; Ashutosh Chilkoti
Journal:  Cancer Res       Date:  2012-11-15       Impact factor: 12.701

Review 9.  Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles.

Authors:  William T Phillips; Ande Bao; Andrew J Brenner; Beth A Goins
Journal:  Adv Drug Deliv Rev       Date:  2014-07-09       Impact factor: 15.470

10.  Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.

Authors:  Hirohisa Nakamae; D Scott Wilbur; Donald K Hamlin; Monica S Thakar; Erlinda B Santos; Darrell R Fisher; Aimee L Kenoyer; John M Pagel; Oliver W Press; Rainer Storb; Brenda M Sandmaier
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.